AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
0
0
0
-
Cost of Revenue
-
-
0
-
Gross Profit
-
-
0
-
Operating Expenses
Research Development
5,400
15,589
23,285
17,306
Selling General and Administrative
8,458
10,897
11,674
9,941
Total Operating Expenses
13,858
26,504
34,959
27,247
Operating Income or Loss
-13,858
-26,504
-34,959
-27,247
Interest Expense
-
0
0
0
Total Other Income/Expenses Net
1,090
2,782
2,210
8,962
Income Before Tax
-12,740
-23,500
-32,574
-18,141
Income Tax Expense
-
-3,550
-8,687
-
Income from Continuing Operations
-12,740
-19,950
-32,574
-18,141
Net Income
-12,740
-19,950
-32,574
-18,141
Net Income available to common shareholders
-12,740
-19,950
-32,574
-18,141
Reported EPS
Basic
-
-1.26
-3.00
-2.00
Diluted
-
-1.26
-3.00
-2.00
Weighted average shares outstanding
Basic
-
15,807
12,473
11,777
Diluted
-
15,807
12,473
11,777
EBITDA
-
-23,461
-34,959
-18,101